Heterogeneity of kinase inhibitor resistance mechanisms in GIST (Q37218711)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Heterogeneity of kinase inhibitor resistance mechanisms in GIST (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

B Liegl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

I Kepten

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

C Le

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

M Zhu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

G D Demetri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

C D M Fletcher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

C L Corless

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

J A Fletcher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

64-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

10 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

PDGFRA activating mutations in gastrointestinal stromal tumors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2693040

Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18623623

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18623623

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PATH.2382

1 reference

19 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

PubMed publication ID

18623623

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18623623%20AND%20SRC:MED&resulttype=core&format=json